Lodestone Biomedical
Lebanon, US · Founded 2015 · Delaware corporation
Lodestone Biomedical develops biosensing and monitoring tools for the tumor microenvironment in preclinical cancer research models, enabling detection of immune response during early-stage drug discovery. Its research-use-only products and services serve drug development researchers conducting preclinical studies.
BiotechDeep TechHealthtech
Founders & leadership
SD
Solomon DiamondExecutive Officer, Director
LV
Lidia ValdesExecutive Officer, Director
Reported raises · per SEC filings
Form D private placements▶$75KraisedJul 2025 · 1 investors · BiotechnologyRule 506(b)
▶$75KraisedJul 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Solomon DiamondExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $75K
- First sale
- Jun 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$450KraisedDec 2021 · 6 investors · BiotechnologyRule 506(b)
▶$450KraisedDec 2021 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Solomon DiamondExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $450K
- First sale
- Dec 2021
- Incorporated
- Limited Liability Company, New Hampshire
- Federal exemptions
- 06b
▶$110KraisedApr 2020 · 3 investors · BiotechnologyRule 506(b)
▶$110KraisedApr 2020 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Solomon DiamondExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $110K
- Minimum investment
- $5K
- First sale
- Mar 2020
- Incorporated
- Limited Liability Company, New Hampshire, 2015
- Federal exemptions
- 06b
▶$550KraisedJul 2017 · 7 investors · BiotechnologyRule 506(b)
▶$550KraisedJul 2017 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Solomon DiamondExecutive Officer, Director
- Lidia ValdesExecutive Officer, Director
- Offering amount
- $600K
- Amount sold
- $550K
- Minimum investment
- $5K
- Proceeds to insiders
- $100K
- First sale
- Jul 2017
- Incorporated
- Limited Liability Company, New Hampshire, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $400K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.